{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T12:46:24Z","timestamp":1781181984476,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004721","name":"University of Tokyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40801-025-00481-2","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T19:27:31Z","timestamp":1738351651000},"page":"145-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Trends in Reports of Statin-Associated Immune-Mediated Necrotizing Myopathy Using the Japanese Adverse Drug Event Report Database"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3289-822X","authenticated-orcid":false,"given":"Akina","family":"Takami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6804-5585","authenticated-orcid":false,"given":"Gen","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9633-5831","authenticated-orcid":false,"given":"Takumi","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3187-0900","authenticated-orcid":false,"given":"Koki","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-6916","authenticated-orcid":false,"given":"Ataru","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"481_CR1","unstructured":"Ministry of Health, Labour and Welfare. Vital Statistics 2023. https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/jinkou\/geppo\/nengai23\/index.html. Accessed 5 Aug 2024 (in Japanese)."},{"key":"481_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jacl.2017.01.006","volume":"11","author":"JM Backes","year":"2017","unstructured":"Backes JM, Ruisinger JF, Gibson CA, Moriarty PM. Statin-associated muscle symptoms-managing the highly intolerant. J Clin Lipidol. 2017;11:24\u201333.","journal-title":"J Clin Lipidol"},{"key":"481_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.17925\/EE.2022.18.2.89","volume":"18","author":"MS Jeeyavudeen","year":"2022","unstructured":"Jeeyavudeen MS, Pappachan JM, Arunagirinathan G. Statin-related muscle toxicity: an evidence-based review. touchREV Endocrinol. 2022;18:89\u201395.","journal-title":"touchREV Endocrinol"},{"key":"481_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/antib13010012","volume":"13","author":"S Julien","year":"2024","unstructured":"Julien S, Challier I, Malleter M, Jouen F, Drouot L, Boyer O. Immune-mediated necrotizing myopathy (IMNM): a story of antibodies. Antibodies (Basel). 2024;13:12.","journal-title":"Antibodies (Basel)"},{"key":"481_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, the Netherlands. Neuromuscul Disord. 2004;14:337\u201345.","journal-title":"Neuromuscul Disord"},{"key":"481_CR6","doi-asserted-by":"crossref","unstructured":"Allenbach Y, Mammen AL, Benveniste O, Stenzel W, Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC international workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, the Netherlands, 14\u201316 October 2016. Neuromuscul Disord 2018;28:87\u201399.","DOI":"10.1016\/j.nmd.2017.09.016"},{"key":"481_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/MD.0000000000000028","volume":"93","author":"Y Allenbach","year":"2014","unstructured":"Allenbach Y, Drouot L, Rigolet A, Charuel JL, Jouen F, Romero NB, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore). 2014;93:150\u20137.","journal-title":"Medicine (Baltimore)"},{"key":"481_CR8","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1002\/art.34673","volume":"64","author":"JL Werner","year":"2012","unstructured":"Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum. 2012;64:4087\u201393.","journal-title":"Arthritis Rheum"},{"key":"481_CR9","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMc1506163","volume":"373","author":"AL Mammen","year":"2015","unstructured":"Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med. 2015;373:1680\u20132.","journal-title":"N Engl J Med"},{"key":"481_CR10","unstructured":"Takahashi S, Okamura E, Sakamoto M, Mashimo Y, Ozawa Y, Uchino T, et al. A case report of necrotizing myositis with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibody positive that occurred after discontinuation of statin. In: Program and proceedings. p 335. Annual scientific meeting of the Japan Atherosclerosis Society 2018."},{"key":"481_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2147\/TCRM.S197941","volume":"16","author":"E Tiniakou","year":"2020","unstructured":"Tiniakou E. Statin-associated autoimmune myopathy: current perspectives. Ther Clin Risk Manag. 2020;16:483\u201392.","journal-title":"Ther Clin Risk Manag"},{"key":"481_CR12","unstructured":"Pharmaceuticals and Medical Devices Agency. Revisions of precautions atorvastatin calcium hydrate, simvastatin, pitavastatin calcium hydrate, pravastatin sodium, fluvastatin sodium, rosuvastatin calcium. https:\/\/www.pmda.go.jp\/files\/000214532.pdf. Accessed 4 Sept 2024 (in Japanese)."},{"key":"481_CR13","unstructured":"Pharmaceuticals and Medical Devices Agency. Revision of \u201cprecautions\u201d for ethical drugs containing HMG-CoA reductase inhibitors. 2016. https:\/\/www.pmda.go.jp\/files\/000214541.pdf. Accessed 4 Sept 2024 (in Japanese)."},{"key":"481_CR14","unstructured":"Pharmaceuticals and Medical Devices Agency. Revisions of precautions atorvastatin calcium hydrate, simvastatin, pitavastatin calcium hydrate, pravastatin sodium, fluvastatin sodium, rosuvastatin calcium. 2016. https:\/\/www.pmda.go.jp\/files\/000219549.pdf. Accessed 4 Sept 2024."},{"key":"481_CR15","unstructured":"Pharmaceuticals and Medical Devices Agency. Summary of investigation results fluvastatin sodium, pravastatin sodium, simvastatin, atorvastatin calcium hydrate, pitavastatin calcium hydrate, rosuvastatin calcium, amlodipine besilate\/atorvastatin calcium hydrate. 2016. https:\/\/www.pmda.go.jp\/files\/000214568.pdf. Accessed 4 Sept 2024."},{"key":"481_CR16","unstructured":"Pharmaceuticals and Medical Devices Agency. Japanese Adverse Drug Event Report database (JADER). https:\/\/www.pmda.go.jp\/safety\/info-services\/drugs\/adr-info\/suspected-adr\/0003.html. Accessed 4 Sept 2024 (in Japanese)."},{"key":"481_CR17","unstructured":"JMDC Inc. JMDC Claims Database. https:\/\/www.jmdc.co.jp\/jmdc-claims-database. Accessed 4 Sept 2024 (in Japanese)."},{"key":"481_CR18","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/cpt.81","volume":"97","author":"J Bohn","year":"2015","unstructured":"Bohn J, Kortepeter C, Mu\u00f1oz M, Simms K, Montenegro S, Dal Pan G. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs. Clin Pharmacol Ther. 2015;97:508\u201317.","journal-title":"Clin Pharmacol Ther"},{"key":"481_CR19","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/cpt.1342","volume":"105","author":"A Takami","year":"2019","unstructured":"Takami A, Hirata K, Ishiguro C, Hanaoka H, Uyama Y. Lower proportion of spontaneous adverse event reports for generic drugs by comparison with original branded drugs at the postmarket stage in Japan. Clin Pharmacol Ther. 2019;105:1471\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"481_CR20","unstructured":"Ministry of Health, Labour and Welfare. Press release\u2014ratio of generic drugs used by insurers (as of March 2023). October 20, 2023. https:\/\/www.mhlw.go.jp\/stf\/newpage_35242.html. Accessed 18 Aug 2024 (in Japanese)."},{"key":"481_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/ni0901-777","volume":"2","author":"CC Whitacre","year":"2001","unstructured":"Whitacre CC. Sex differences in autoimmune disease. Nat Immunol. 2001;2:777\u201380.","journal-title":"Nat Immunol"},{"key":"481_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1177\/08971900211040291","volume":"36","author":"R Barrons","year":"2023","unstructured":"Barrons R. Statin-associated autoimmune myopathy: review of the literature. J Pharm Pract. 2023;36:383\u201393.","journal-title":"J Pharm Pract"},{"key":"481_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00228-018-2589-z","volume":"75","author":"D Essers","year":"2019","unstructured":"Essers D, Sch\u00e4ublin M, Kullak-Ublick GA, Weiler S. Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase. Eur J Clin Pharmacol. 2019;75:409\u201316.","journal-title":"Eur J Clin Pharmacol"},{"key":"481_CR24","unstructured":"Ministry of Health, Labour and Welfare. Overview of medical facilities survey and hospital report in 2022. https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/iryosd\/22\/dl\/11gaikyou04.pdf. Accessed 18 Aug 2024 (in Japanese)."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00481-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-025-00481-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-025-00481-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T18:28:09Z","timestamp":1739644089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-025-00481-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["481"],"URL":"https:\/\/doi.org\/10.1007\/s40801-025-00481-2","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"9 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the conduct of this study or the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ethics approval was not applicable to this study based on the Ethical Guidelines for Medical and Health Research Involving Human Subjects issued by the MHLW, since only completely encrypted data were used.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The datasets generated for this manuscript are available in the JADER database ().","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Akina Takami developed the concept and the study design; Akina Takami, Gen Terashima, and Takumi Tajima analyzed the data; and all authors wrote, reviewed, and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Akina Takami and Ataru Igarashi are members of the Department of Health Policy and Public Health (formerly known as the Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, which received an unrestricted grant from Takeda Pharmaceutical Co. Ltd.); Gen Terashima and Takumi Tajima are employees of JMDC, Inc.; Koki Yamashita is the president of Maxwell International, Inc., wherein he provides medical writing and clinical study consultation services to academic, pharmaceutical, biotechnology, and medical device entities; and Ataru Igarashi reports receiving remuneration from AstraZeneca K.K.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}